RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies |
| |
Authors: | Ke-Da Yu Chen Yang Lei Fan Ao-Xiang Chen Zhi-Ming Shao |
| |
Institution: | (1) Department of Breast Surgery, Cancer Center/Cancer Institute, Fudan University, 399 Ling-Ling Road, Shanghai, 200032, People’s Republic of China;(2) Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;(3) Institutes of Biomedical Science, Fudan University, Shanghai, People’s Republic of China; |
| |
Abstract: | A single-nucleotide polymorphism (SNP) in the 5′-untranslated region (UTR) of RAD51, 135G>C (rs1801320), was reported to be
associated with an increased risk of breast cancer among BRCA2 as well as BRCA1 carriers. A few studies have also investigated
the genetic contribution of RAD51 135G>C to the risk of sporadic breast cancers or breast cancer in non-BRCA1/2 carriers,
though the results are yet controversial and inconclusive. We, in this study, performed a more precise estimation of the relationship
between 135G>C and breast cancer among non-BRCA1/2 mutation carriers by meta-analyzing the currently available evidence from
the literature. A total of 12 studies involving 7,065 cases and 6,981 controls were identified. Crude odds ratios (ORs) with
95% confidence intervals (CIs) were used to assess the strength of association. When all the studies were pooled into the
meta-analysis, there was no evidence for a significant association between 135G>C and breast cancer risk in non-BRCA1/2 mutation
carriers (for CC vs. GG: OR = 0.995, 95%CI: 0.741–1.336; for GC vs. GG: OR = 0.959, 95%CI: 0.869–1.057; for dominant model:
OR = 0.988, 95%CI: 0.902–1.082; and for recessive model: OR = 1.037, 95%CI: 0.782–1.376). We also performed subgroup analysis
by ethnicity (Caucasian) as well as did analysis using the studies fulfilling Hardy–Weinberg equilibrium, and the results
did not change. In summary, the present meta-analysis suggests that the RAD51 135G>C does not modify breast cancer risk in
non-BRCA1/2 mutation carriers. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|